Beyond the Science: Commercial Implications From ASCO 2017
Published: | Updated:
Four strategic takeaways from this year's that are important for pharma oncology leaders.
Maria Whitman
Advertisement
Articles by Maria Whitman
Advertisement
Latest Updated Articles
Beyond the Science: Commercial Implications From ASCO 2017Published: August 21st 2017 | Updated: November 15th 2020
Advertisement
Advertisement
Trending on PharmExec
1
Patent Term Extension: Challenges with Defining and Claiming Approved Biologics
2
Novo Nordisk Invests $506 Million in Ireland Manufacturing Facility Expansion
3
FDA Approves New Indication of Palynziq for Patients 12 Years and Older with Phenylketonuria
4
Real-World Data Brings New Insights to Natural History of Disease Studies
5